Content about Pancreatitis

May 31, 2013

A new, higher-dose formulation of a drug used to treat pancreatic disorders is now available, the drug's manufacturer said.

NORTH CHICAGO, Ill. — A new, higher-dose formulation of a drug used to treat pancreatic disorders is now available, the drug's manufacturer said.

AbbVie announced the launch of the new formulation of Creon (pancrelipase) delayed-release capsules. The drug is used to treat exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, removal of the pancreas and other conditions. The new strength is the highest-dose pancreatic enzyme replacement therapy available in the United States, AbbVie said.

April 3, 2012

Drug maker Amylin Pharmaceuticals has filed for regulatory approval of a drug to treat diabetes and elevated triglycerides in the bloodstream in children and adults with a rare disorder.

SAN DIEGO — Drug maker Amylin Pharmaceuticals has filed for regulatory approval of a drug to treat diabetes and elevated triglycerides in the bloodstream in children and adults with a rare disorder.

March 1, 2012

The Food and Drug Administration has approved two new drugs for pancreatic disorders, the agency said Thursday.

SILVER SPRING, Md. — The Food and Drug Administration has approved two new drugs for pancreatic disorders, the agency said Thursday.

The FDA announced the approval of Aptalis Pharma's Ultresa and Viokase, both generically known as pancrelipase. Ultresa is a delayed-release capsule for children and adults with cystic fibrosis, which affects the lungs and other organs, while Viokase is meant for use with a proton-pump inhibitor in adults who can't digest food because of pancreatitis or surgical removal of the pancreas.

September 21, 2011

Researchers at the University of California Los Angeles said they have found a possible link between two new drugs for Type 2 diabetes and cancers of the pancreas and thyroid, according to a new study published in the journal Gastroenterology.

LOS ANGELES — Researchers at the University of California Los Angeles said they have found a possible link between two new drugs for Type 2 diabetes and cancers of the pancreas and thyroid, according to a new study published in the journal Gastroenterology.

The researchers, at UCLA's Larry L. Hillblom Islet Research Center, examined incidents reported in the Food and Drug Administration's adverse event database between 2004 and 2009 among patients using Byetta (exenatide), made by Eli Lilly and Amylin Pharmaceuticals, and Merck's Januvia (sitagliptin).

January 17, 2011

A Food and Drug Administration advisory committee voted last week not to recommend approval of a drug from Eli Lilly.

INDIANAPOLIS — An advisory committee of the Food and Drug Administration voted last week not to recommend approval of a drug from Eli Lilly.

The FDA Gastrointestinal Drugs Advisory Committee said it recommended that additional studies be conducted prior to the FDA's review of liprotamase, a nonporcine pancreatic enzyme replacement therapy, for the treatment of exocrine pancreatic insufficiency. EPI is a disease resulting from cystic fibrosis, removal of the pancreas, chronic pancreatitis and other conditions.

July 20, 2010

Drug maker Eli Lilly has finished its acquisition of a company developing a pancreatic disorder...

July 5, 2010

Drug maker Eli Lilly is moving to acquire a company developing an enzyme-replacement therapy, Lilly...

May 2, 2010

The Food and Drug Administration has granted an additional approval to a pancreatic enzyme drug...